DCPG

DCPG ((S)-3,4-DCPG) is a drug used in scientific research, which acts as a potent and subtype-selective agonist for the metabotropic glutamate receptor mGluR₈. It has anticonvulsant effects in animal studies,^[1][2] and has also been investigated as a possible treatment for hyperalgesia.^[3]

DCPG

Identifiers
IUPAC name 4-[(1S)-1-amino-2-hydroxy-2-oxoethyl]phthalic acid
CAS Number	201730-11-2 Y
PubChem CID	16062593
IUPHAR/BPS	1407
ChemSpider	17222214 N
UNII	W3Y53JA9W3
CompTox Dashboard (EPA)	DTXSID60581628
ECHA InfoCard	100.161.870
Chemical and physical data
Formula	C10H9NO6
Molar mass	239.183 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(O)[C@@H](N)c1cc(c(C(=O)O)cc1)C(=O)O
InChI InChI=1S/C10H9NO6/c11-7(10(16)17)4-1-2-5(8(12)13)6(3-4)9(14)15/h1-3,7H,11H2,(H,12,13)(H,14,15)(H,16,17)/t7-/m0/s1 N Key:IJVMOGKBEVRBPP-ZETCQYMHSA-N N
NY (what is this?)  (verify)

References

1. Moldrich RX, Chapman AG, De Sarro G, Meldrum BS (August 2003). "Glutamate metabotropic receptors as targets for drug therapy in epilepsy". European Journal of Pharmacology. 476 (1–2): 3–16. doi:10.1016/s0014-2999(03)02149-6. PMID 12969743.
2. Folbergrová J, Druga R, Haugvicová R, Mares P, Otáhal J (March 2008). "Anticonvulsant and neuroprotective effect of (S)-3,4-dicarboxyphenylglycine against seizures induced in immature rats by homocysteic acid". Neuropharmacology. 54 (4): 665–75. doi:10.1016/j.neuropharm.2007.11.015. PMID 18191956. S2CID 20697899.
3. Marabese I, de Novellis V, Palazzo E, Scafuro MA, Vita D, Rossi F, Maione S (February 2007). "Effects of (S)-3,4-DCPG, an mGlu8 receptor agonist, on inflammatory and neuropathic pain in mice". Neuropharmacology. 52 (2): 253–62. doi:10.1016/j.neuropharm.2006.04.006. PMID 17113112. S2CID 25646746.